Sagiv-Barfi et al. [34] investigated the synergistic effects of ibrutinib in combination with anti-PD-L1 antibodies on different cell lines, including 4t1-Luc, a triple-negative breast cancer (TNBC) cell line. Here, CD274 is linked to triple-negative breast carcinoma.